Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 101 - 150 out of 127,969

Document Document Title
WO/2024/102883A1
Described herein are methods of treating, ameliorating and/or preventing a stress- related disorder in a subject in need thereof. The method, in certain embodiments, includes administering to the subject a therapeutically effective amoun...  
WO/2023/034793A9
Disclosed herein is the effect that IL-33 has on the tumor microenvironment. In one aspect, disclosed herein are methods for treating a cancer, inhibiting TH2 pro-tumorigenic cytokines in the TME, inhibiting secretion of IL-33 in the TME...  
WO/2024/100270A1
The present invention relates to novel pore monomer conjugates comprising pore monomers and functionalised partner molecules, pore complexes formed from the conjugates and their uses in analyte detection and characterisation.  
WO/2024/059699A3
Described herein are methods and compositions for generating single sex offspring using trans-splicing approach. In particular, methods and compositions are provided to generate single sex and genetically modified offspring. These techni...  
WO/2024/102865A2
Provided herein is a synthetic polypeptide derived from High Mobility Group Box 1 (HMGB 1) host protein that can both disrupt bacterial biofilms and prevent Neutrophil Extracellular Trap (NET) formation. Also provided herein are methods ...  
WO/2024/102697A1
Disclosed herein are vaccine compositions, in particular, polyvalent icosahedral compositions for presentation of a rotavirus antigen. The disclosed compositions may contain an S particle made up of recombinant fusion proteins that furth...  
WO/2024/102818A1
Described herein is a method of treating a human patient with a solid tumor, the method including administering to the human patient an effective amount of a fusion polypeptide comprising a tissue factor fragment and a covalently linked ...  
WO/2024/101942A1
The present invention relates to cells genetically engineered to express a peptide or a fragment thereof which can inhibit a transforming growth factor-β (TGF-β) signaling pathway.  
WO/2024/099428A1
Provided are a membrane fusion inhibitor for inhibiting HIV and a drug-resistant strain thereof, a derivative thereof, a pharmaceutical composition thereof, and a pharmaceutical use thereof.  
WO/2024/102605A1
The present disclosure relates generally to improved methods of preparing glycoconjugates. The methods comprise using a reducing mixture containing acetoxyborohydrides prepared in-situ for conjugating a saccharide to a carrier protein.  
WO/2024/102707A1
The current disclosure provides methods and compositions that provide for the insertion of transgenes in stem or progenitor cells without the deleterious effects to T cell differentiation by in vitro T cell differentiation methods. To ac...  
WO/2024/099346A1
The present invention provides use of a compound as represented by formula I or a pharmaceutically acceptable salt or ester thereof in the preparation of a drug for treating ASC-caspase-1 pathway-based inflammasome activation-mediated di...  
WO/2024/044766A3
Disclosed are methods and compositions for inhibiting endocytosis and enhancing function of hematopoietic stem cells. Certain aspects are directed to increasing MYCT1 activity or expression to improve hematopoietic stem cell self-renewal...  
WO/2024/102995A1
Disclosed herein, are compositions and methods using Chlamydia Muridarum organisms in the treatment and prevention of human Chlamydia trachomatis infections in a subject. Also, disclosed herein are compositions and methods for eliciting ...  
WO/2024/099163A1
Disclosed is use of a Zea mays amino acid transporter and a coding gene thereof in plant disease resistance. Specifically disclosed are a protein having the amino acid sequence of SEQ ID No. 3 and a coding gene thereof. The present inven...  
WO/2024/100067A1
Described herein is a dairy product, or a replica thereof, supplemented with a hemeprotein, and a method for preparing such a dairy product, or a replica thereof.  
WO/2024/102693A2
Provided herein are variant human IL18 proteins including proteins and constructs including such. Various variant IL18 proteins with modifications to reduce heterogeneity and/or reduce affinity/potency and/or improve stability and/or imp...  
WO/2024/059667A3
The disclosure is directed in part to variant capsid polypeptides that can be used to deliver pay loads.  
WO/2024/101710A1
The present invention relates to a pharmaceutical composition for prevention or treatment of glioma, comprising a multiple-epitope peptide, and more specifically to a technique using a multiple-epitope peptide for the use of prevention, ...  
WO/2024/102361A1
A pharmaceutical combination includes a beta-lactam antibiotic alone or in combination with a beta-lactamase inhibitor useful for treating multiple myeloma, monoclonal gammopathy of undetermined significance, and smoldering multiple myel...  
WO/2023/076272A9
In certain embodiments, provided are methods for increasing the efficiency of dicot and gymnosperm transformation using BBM with no or minimal plant phenotype. Vector designs for achieving these results are also provided, as are methods ...  
WO/2024/102965A1
Disclosed herein are designer extracellular vesicles (EVs) that target muscle cells. For example, in some embodiments, the EVs are decorated NHERF1, NHERF2, a fusion protein containing an E8 fragment of laminin and an exosomal or lysosom...  
WO/2024/098216A1
A peptide consisting of 20 to 30 amino acid residues derived from amino acid position 120 to 171 of mature allergen Fel d 4 is provided as well as fusion proteins comprising said peptide.  
WO/2024/102556A1
The present disclosure is generally related to genetically modified filamentous fungal strains (cells) and their use in the production of proteins of interest. Certain embodiments provide, inter alia, methods and compositions for the des...  
WO/2024/044750A3
The present disclosure features allogeneic modified cells (e.g., T- or NK-cells) having increased persistence, increased resistance to immune rejection, or decreased risk of eliciting a host-versus-graft reaction, or a combination thereo...  
WO/2024/101433A1
A glycosylated neuropeptide derivative comprising a neuropeptide sequence, a membrane-penetration-promoting sequence, an endosomal-escape-promoting sequence, and a sugar chain.  
WO/2024/101962A1
The present invention relates to cells that have been genetically engineered to express a peptide or fragment thereof capable of inhibiting the transforming growth factor-β (TGF-β) signaling pathway, in conjunction with a chimeric anti...  
WO/2024/050512A3
Disclosed herein are compositions and methods for treating, and for the preventative treatment of Lyme disease. Also disclosed herein are compositions and methods for detecting and diagnosing infection by a Borrelia sp.  
WO/2024/055027A3
Provided are modified bacteria, compositions comprising the modified bacteria and Rare Earth Elements (REEs), and method of using the modified bacteria to separate REEs from a variety of materials and liquids.  
WO/2024/102436A1
Provided herein is an engineered controllable membrane targeting system based on triggered exposure of a cryptic acylation signal, a calcium-regulated protease that can be used to expose this cryptic acylation signal, a means of coupling...  
WO/2024/059862A3
The disclosure relates to peptide compositions, e.g., silk fibroin derived peptide compositions. Wherein a peptide or protein fragment comprising a plurality of amino acids selected from M, R, V, K, T, F, I, L, C, A, Q, Y, N, D, E, G, S,...  
WO/2024/100557A1
Provided are glycoprotein NMB (GPNMB)-binding chimeric antigen receptors (CARs). In some embodiments, a CAR of the present disclosure comprises an extracellular GPNMB-binding domain (e.g., a single chain antibody, such as an scFv), a tra...  
WO/2024/102919A1
The present disclosure relates compositions and methods for treating, preventing, reducing, and/or ameliorating a cancer.  
WO/2024/059634A3
The present application provides for polypeptides comprising an IL-21 polypeptide, IL-12 polypeptide, and/or a IL-15 polypeptide, and/or a IL-15 receptor polypeptide; immune checkpoint polypeptides; compositions comprising the same; and ...  
WO/2024/101434A1
This physiologically-active peptide derivative for the treatment of eye diseases comprises a physiologically-active peptide sequence and a functional sequence comprising a membrane permeation-promoting sequence and an endosomal escape-pr...  
WO/2024/100399A1
Disclosed is a recombinant mechanosensory amino acid polymer comprising at least two amino acid monomer sequences and cross linking means, in which the monomers include: one or more helical structure; at least one amino acid substitution...  
WO/2024/103049A1
Disclosed are exosomes comprising an extracellular CD33 binding motif fused to a transmembrane protein. Disclosed are methods of making a cell derived exosome comprising: transfecting a plasmid into cells, wherein the plasmid comprises a...  
WO/2024/101559A1
The present invention relates to a fusion protein containing IL-22 and a use thereof. The fusion protein containing IL-22 of the present invention exhibits excellent therapeutic effects and stability in inflammatory bowel diseases, and t...  
WO/2024/102984A1
The disclosure relates to isolated nucleic acids comprising opioid receptor promoter regions and methods and compositions comprising said isolated nucleic acids.  
WO/2024/102988A1
This document relates to methods and materials for treating a mammal (e.g., a human) having, or at risk of developing, a proteinopathy. For example, one or more nucleoporin polypeptides (and/or nucleic acids designed to express a nucleop...  
WO/2024/102954A1
Disclosed are nucleic acids encoding fusion proteins containing a target binding domain, a cleavage domain cleavable by A Disintegrin and Metalloproteinase (ADAM) 17, and a transmembrane domain.  
WO/2024/102604A1
Anti-5T4 antibodies and antigen-binding fragments thereof and chimeric antigen receptors (CARs) comprising anti-5T4 antigen-binding domains are described. Also described are nucleic acids encoding the antibodies and CARs, compositions co...  
WO/2024/006281A3
The present disclosure pertains to modified immune cells comprising chimeric switch receptors and methods of using and making immune cells comprising chimeric switch receptors. The present disclosure also pertains to modified immune cell...  
WO/2024/064637A3
Compositions comprising an RNA molecule comprising a guide sequence portion having 17-50 contiguous nucleotides containing nucleotides in the sequence set forth in any one of SEQ ID NOs: 1-11121 and methods and uses thereof.  
WO/2024/064640A3
Disclosed herein are chimeric antigen receptors (CARs) comprising an antigen binding site that recognizes citrullinated polypeptides. Citru llinated polypeptides, such as citrullinated vimentin, are expressed in the skin lesions of subje...  
WO/2024/094237A1
Novel derivatives of human insulin are described that have binding affinities for the IGF-1 receptor surprisingly comparable to human IGF-1, while having higher affinities for both isoforms of the insulin receptor than human insulin. The...  
WO/2024/097713A1
In one embodiment, the present disclosure provides hypoallergenic peanut allergens Ara h 6 variants wherein at least one epitope recognized by anti-Ara h 6 antibodies has been modified, thereby having reduced or abolished antibody bindin...  
WO/2024/097901A1
. Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. Also provided are derivative cells having stable and functional...  
WO/2024/097904A1
This disclosure provides, among other things, an engineered immunosuppressive (e.g., CD4+) T cell comprising a molecular circuit comprising the following components: (a) a central nervous system (CNS)-specific binding-triggered transcrip...  
WO/2024/095149A1
The present invention relates to hydrolysed collagen products or collagen hydrolysates, a process for their preparation and their uses as anti-inflammatory and/or analgesic active ingredients for topical applications such as for example ...  

Matches 101 - 150 out of 127,969